Cargando…
PDX: Moving Beyond Drug Screening to Versatile Models for Research Discovery
Patient-derived xenografts (PDXs) are tools of the trade for many researchers from all disciplines and medical specialties. Most endocrinologists, and especially those working in oncology, commonly use PDXs for preclinical drug testing and development, and over the last decade large collections of P...
Autores principales: | Risbridger, Gail P, Lawrence, Mitchell G, Taylor, Renea A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566391/ https://www.ncbi.nlm.nih.gov/pubmed/33094211 http://dx.doi.org/10.1210/jendso/bvaa132 |
Ejemplares similares
-
To target or not to target the enemy within localized prostate cancer
por: Risbridger, Gail, et al.
Publicado: (2013) -
SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease
por: Risbridger, Gail, et al.
Publicado: (2019) -
Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field
por: Williams, Juliet A.
Publicado: (2018) -
Multidimensional Atomic Force Microscopy: A Versatile Novel Technology for Nanopharmacology Research
por: Lal, Ratnesh, et al.
Publicado: (2010) -
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids
por: Choo, Nicholas, et al.
Publicado: (2021)